Please assess the completion status of the following clinical trial:

Trial Title: Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* Age ≥ 45 years~* Naïve to integrase inhibitor and etravirine~* At least 6 months of stable antiretroviral therapy (ART) including a boosted protease inhibitor, whatever the number of combined drugs~* HIV-RNA plasma VL ≤ 50 copies/mL during the last 24 months prior to screening visit (Week-6/Week-4), documented by at least 4 time-points with no more than one blip in HIV-RNA plasma viral load between 51 and 200 copies/mL~* HIV-RNA plasma VL ≤ 50 copies/mL at screening visit (Week-6/Week-4)~* A genotype is available (on amplified DNA at Week-6/Week-4 Visit and/or on RNA in the medical history of the patient) and shows a virus sensitive to ETR OR no genotype is available (amplification failure on DNA at Week-6/Week-4 Visit and no genotype in the medical history of the patient), there are no virological failure on NNRTI in the medical history~* CD4+ lymphocytes \> 200 cells/mm3~* Creatinine \< 2.5 x ULN~* CPK (Creatine Phospho Kinase) \< 6 ULN (Upper Limit of Normal)~* AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase) \< 5 ULN~* Hemoglobin \> 10 g/dL~* Platelets \> 100 000/mm3~* Negative urinary pregnancy test and use of efficient contraception for women of childbearing potential~* For French participants only: subject enrolled in or a beneficiary of a Social Security programme (State Medical Aid or AME is not a Social Security programme), article L1121-11 of the Public health code~* Patients with a coverage from a social health~* Signed informed consent~Exclusion Criteria:~* Previous exposure to raltegravir or etravirine~* Presence of any documented integrase inhibitor mutation on DNA genotype at Week-6/Week-4 and/or on RNA in the medical history of the patient~* Positive hepatitis B HBsAg or Positive HBc Ac and negative HBs Ac~* HIV-2 infection~* Active viral hepatitis C requiring a specific treatment during the 24 months of the trial~* Patient with a history of non-compliance or irregular follow-up~* Initiation of a concomitant anti-hypercholesterolemia (e.g. statins) or antidiabetic treatment within the last 3 months prior the screening visit (Week-6 /Week-4)~* Patient using: Clopidogrel (Plavix®), Prasugrel (Effient®), Ticagrelor (Brilinta®), Ticlopidine (Ticlid®), Flurbiprofen (Antadys® - Cebutid®), Rifampin (Rifampicin® - Rifadin® - RofactMC - Rifater®), Rifapentine (Priftin®), St John's wort, Carbamazepine (Tegretol®), Phenobarbital, Phenytoin (Dilantin®),Avanafil (Stendra™), Triazolam (Halcion®)~* Concomitant treatment using interferon, interleukins or any other immunotherapy or chemotherapy~* Concomitant prophylactic or curative treatment for an opportunistic infection~* All conditions (use of alcohol, drugs, etc.) judged by the investigator to possibly interfere with trial protocol compliance, adherence and/or trial treatment tolerance~* Subjects under judicial protection due to temporarily and slightly diminished mental or physical faculties, or under legal guardianship~* Subjects participating in another clinical trial evaluating different therapies and including an exclusion period that is still in force during the screening phase~* Pregnant women or breastfeeding women

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- raltegravir and etravirine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).